Ovid Therapeutics opened lower at $2.77, compared with its previous close of $2.78. In the last trading session, the stock traded between $2.51 and $2.77. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Ovid Therapeutics is now worth
$ 72.56
Resulting in a loss of
$ 27.44 (27.44%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.23 (-8.38%)
Day High
$2.77
Day Low
$2.51
Day Open
$2.77
Prev Close
$2.78
Volume
26,26,126
1W Return
-6.91%
1M Return
5.90%
3M Return
-1.85%
6M Return
-8.71%
1Y Return
88.67%
Fundamentals
Market Cap ($ Mn)
481
PE Ratio
-
PB Ratio
2.46
PEG Ratio
-
ROE
-24.28%
ROCE
-20.62%
EPS (TTM)
$-0.11
Investment Returns
1 Week
-6.91%
1 Month
5.90%
3 Months
-1.85%
6 Months
-8.71%
9 Months
60.19%
Financials
Quarterly
All values in $ Mn
0.1
Mar 25
6.3
Jun 25
0.1
Sep 25
0.7
Dec 25
0.7
Jun 26
0.0
Sep 26
Updates
10Nov
Ovid Therapeutics Q3 Results: Loss widens to $(0.10) per share, misses estimates
Reported EPS of $(0.10) missed the consensus estimate of $(0.09) by 11.11%. Quarterly loss narrowed 41.18% YoY from $(0.17) in the prior year period. Short-term earnings shortfall contrasts with significant year-over-year improvement in losses.
2 days ago
8Jul
Ovid Therapeutics promotes Charles Carter to CFO, appoints new business chief
Ovid Therapeutics Inc. announced several strategic appointments to strengthen its executive leadership team. Charles Carter was promoted to Chief Financial Officer, succeeding Jeffrey Rona, who will serve as an advisor through 2027. Kevin Norrett was appointed Chief Business Officer, and Victoria Fort was promoted to Chief Strategy Officer. Eliseo Salinas also joined as Executive R&D Advisor to guide research and development programs.
